About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a company based in Cardiff (United Kingdom) founded in 2000. Biodexa Pharmaceuticals has raised $6.79 million across 1 funding round. Biodexa Pharmaceuticals offers products and services including eRapa, Tolimidone, and MTX110. Biodexa Pharmaceuticals operates in a competitive market with competitors including Modifi Bio, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others.
- Headquarter Cardiff, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biodexa Pharmaceuticals Plc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.79 M (USD)
in 1 rounds
-
Latest Funding Round
$6.79 M (USD), Series A
Dec 21, 2023
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals offers a comprehensive portfolio of products and services, including eRapa, Tolimidone, and MTX110.
Oral formulation for treating familial adenomatous polyposis.
Inhibitor for managing type 1 diabetes symptoms.
Treatment for primary and metastatic brain cancers.
Funding Insights of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals has successfully raised a total of $6.79M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.79 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Biodexa Pharmaceuticals
Investment portfolio details for Biodexa Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biodexa Pharmaceuticals
Detailed financials for Biodexa Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biodexa Pharmaceuticals Comparisons
Peer comparison for Biodexa Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Modifi Bio, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of cancer
|
|
| Locked | Locked | Locked |
Resistance mechanism inhibitors for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Discovering small molecules for diseases caused by protein misfolding such as Parkinson's.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for difficult-to-treat cancers are developed.
|
|
| Locked | Locked | Locked |
Purposeful is engaged in discovering treatments for rare diseases.
|
Detailed competitors of Biodexa Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biodexa Pharmaceuticals
Complete news archive for Biodexa Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals was founded in 2000 and raised its 1st funding round 23 years after it was founded.
Biodexa Pharmaceuticals is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Stephen Stamp is the current CEO of Biodexa Pharmaceuticals.
Biodexa Pharmaceuticals is a funded company, having raised a total of $6.79M across 1 funding round to date.
Biodexa Pharmaceuticals was founded in 2000 and is based in Cardiff, United Kingdom. Focus is placed on the pharmaceutical sector, where therapeutics for brain cancer treatment are developed. The lead candidate, MTX110, consists of a solubilised formulation of the histone deacetylase inhibitor panobinostat. This is targeted at recurrent glioblastoma, medulloblastoma, and paediatric diffuse midline glioma, addressing rare and orphan indications in oncology.
Biodexa Pharmaceuticals's top competitors include Modifi Bio, OncoSynergy and Flag Therapeutics.
Biodexa Pharmaceuticals offers eRapa, Tolimidone, and MTX110.